מודרנה

Moderna and Merck's vaccine, which is custom-made for each patient, achieved its goals in the crucial trial and reduced the risk of disease recurrence and spread compared to Keytruda alone. This is the first positive Phase 3 trial for mRNA-based cancer therapy. Following the announcement: Moderna's stock doubled its value in pre-trade. Prof. Gal Markel, Director of the Doi Center...